Glycoprotein E (VZV) Informations sur la molécule
Molecule Name
Envelope (E) protein
Alias de la molécule
gE
Drug Development Progress
Nombre de médicaments cliniques2
Nombre de médicaments commercialisés0
Phase de R&D la plus avancéePhase 1 Clinical
Alias de la cible
gE-1，Envelope glycoprotein E，gE
Demande de produit
FAQ
What should be matched before selecting a gE assay?
Check species, assay purpose, antigen format, and whether the readout is antigen detection or antibody titer.
Does the gE kit measure viral load?
The listed kits are antibody or antigen ELISA tools; they are not described as viral-load assays.
Can VZV gE reagents support vaccine research?
Yes. Recombinant gE, antigen ELISA kits, and antibody-titer kits support distinct antigen-characterization and immune-response endpoints.
Which antibody reagents are included?
Available options include anti-gE monoclonal antibodies, including an unconjugated and a biotinylated format.
Is a biotinylated gE protein available?
GLE-V82E3 is biotinylated VZV gE with His and AviTag.
Which gE assay kits are available?
Available options include VZV gE ELISA kits and mouse or human anti-VZV IgG-titer serology kits.
Why is VZV gE relevant to antibody research?
gE is an abundant, immunogenic glycoprotein on virus and infected-cell surfaces, making it relevant to antigen-specific antibody studies.
Which VZV gE antigen is available?
The portfolio includes gE from varicella-zoster virus strain Oka vaccine, expressed as a His-tagged recombinant protein.
Asset Licensing Opportunity
Resources
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| LHF-535 | LHF-535; LHF-535-SDD | Phase 1 Clinical | Kineta Inc | Details | |
| SAR-440894 | SAR-440894 | Phase 1 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid) | Chikungunya Fever | Details |
Customer Reviews